5-fluorouracil + bortezomib

This is a combination of two chemotherapeutic agents, 5-fluorouracil and bortezomib. - **5-Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death in rapidly dividing cells. - **Bortezomib** is a reversible inhibitor of the 26S proteasome, blocking protein degradation pathways and inducing apoptosis in cancer cells by affecting multiple signaling cascades including NF-κB inhibition. The combination has been studied for synergistic effects on tumor cell proliferation and apoptosis in various preclinical models (e.g., choriocarcinoma JEG-3 cells, breast cancer 4T1 cells) as well as early-phase clinical trials for advanced colorectal and rectal cancers. The rationale for combining these drugs lies in their complementary mechanisms—bortezomib can sensitize tumor cells to the cytotoxic effects of 5-fluorouracil[2][3][6][7].

Other names

5-FU + bortezomibbortezomib + 5-fluorouracil